Acute Kidney Injury in a Cancer Patient Exposed to Relugolix and Abiraterone
We report the first case of biopsy-proven drug-induced AKI in a cancer patient acutely exposed to relugolix and abiraterone. Whether one of these drugs individually, or their combination, was the cause of the AKI is unknown. Nonetheless, our report is hypothesis-generating for further investigations on the effect of these drugs.
Authors
- Ozan Volkan Yurdakul (ORCID: https://orcid.org/0000-0003-4567-8133)
- Irene Resch
- Shahrokh François Shariat (ORCID: https://orcid.org/0000-0002-6627-6179)
- Moustafa Elleisy (ORCID: https://orcid.org/0000-0001-7375-5357)
- Nicolai Hübner (ORCID: https://orcid.org/0000-0002-1256-1927)
Institutions
- Semmelweis University (HU)
- University of Jordan (JO)
- Tabriz University of Medical Sciences (IR)
- Sechenov University (RU)
- Cornell University (US)
- Charles University (CZ)
- Vienna General Hospital (AT)
- Karl Landsteiner Society (AT)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Urologia Internationalis
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1159/000547373
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00